AI and machine learning for drug discovery
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- BAYER AKTIENGESELLSCHAFT
Global pharmaceutical company contributing drug safety data, clinical expertise, and AI capabilities to Europe's largest health research consortia.
“Recent projects increasingly feature AI/ML keywords — deep learning, predictive models, and big data analytics appear across EHDEN, BigData Heart, and later-phase projects.”
DE59 projects - ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE
Ukrainian medicinal chemistry SME specializing in compound libraries, photopharmacology, bioisostere design, and AI-driven drug discovery.
“Participant in AIDD (advanced ML for drug discovery) and partner in BIGCHEM (big data in chemistry), applying deep learning and generative models to chemical reactions and screening.”
SMEUA7 projects - PFIZER PHARMA GMBH
Pfizer's German subsidiary — industry partner in EU consortia for AI drug discovery and digital cardiovascular disease screening.
“AIDD project (2021-2025) covers generative models, deep learning for chemical reactions, phenotypic screening, yield prediction, and quantum machine learning applied to pharmaceutical R&D.”
PrimaryDE2 projects